Last reviewed · How we verify
NCT03709134
Genomic Markers for Measuring Breast Cancer Response to Neoadjuvant Chemotherapy
trial testing Genomic Markers (CTC/ctDNA) in Breast Cancer in 100 participants. Completed in 1 September 2022.
1 September 2022
Quick facts
| Lead sponsor | Sunnybrook Health Sciences Centre |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 1 October 2019 |
| Primary completion | 1 September 2022 |
| Estimated completion | 1 September 2022 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Genomic Markers (CTC/ctDNA)
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Breast Neoplasms — all drugs for Breast Neoplasms →
- Cancer, Breast — all drugs for Cancer, Breast →
Sponsor
Sunnybrook Health Sciences Centre — full company profile →
Who can join
18 and older, any sex, with Breast Cancer or Breast Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary aim of the study is to identify genomic markers (circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), transcriptomic markers) as biomarkers of response to neoadjuvant chemotherapy (NAC) among patients with invasive breast cancer.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
The Future of Breast Cancer Research in the Survivorship Field.
Soldato D, Arecco L, Agostinetto E, Franzoi MA, et al · · 2023 · cited 20× · PMID 37005952 · DOI 10.1007/s40487-023-00225-8 -
Potential Impact of Preoperative Circulating Biomarkers on Individual Escalating/de-Escalating Strategies in Early Breast Cancer.
Gianni C, Palleschi M, Merloni F, Bleve S, et al · · 2022 · cited 4× · PMID 36612091 · DOI 10.3390/cancers15010096 -
Detection, significance and potential utility of circulating tumor cells in clinical practice in breast cancer (Review).
Rusnáková DŠ, Aziri R, Dubovan P, Jurík M, et al · · 2025 · cited 3× · PMID 39492933 · DOI 10.3892/ol.2024.14756 -
Circulating Tumor Cell Detection for Therapeutic and Prognostic Roles in Breast Cancer.
Ma S, Wang X, Lin PP, Lei L. · · 2025 · cited 1× · PMID 40437761 · DOI 10.1002/cam4.70902
Verify or expand the search:
- PubMed search for NCT03709134
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Sunnybrook Health Sciences Centre trials
Trials by the same sponsor.
- NCT07478705 — Early Detection of Metastatic Recurrence Among Patients With Stage II or III Triple Negative Breast Cancer Using Liquid · NA · not yet recruiting
- NCT07376018 — Ketogenic Diet and Neuromodulation in Treatment Resistant Depression · NA · not yet recruiting
- NCT07350278 — Comparing Virtual Reality Simulation to High Fidelity Simulation as an Educational Modality for Electroconvulsive Therap · NA · not yet recruiting
- NCT07191145 — Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT) · Phase 3 · not yet recruiting
- NCT07308587 — Evaluation of Intercostal Neuralgia in Patients With Chest Tube Insertion After Traumatic Rib Fracture · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03709134 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sunnybrook Health Sciences Centre
- Last refreshed: 20 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03709134.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing